Document is current
Any future updates will be listed below
-
Authors
Vrechi, Talita A. M.
Guarache, Gabriel C.
Oliveira, Rafaela Brito
Guedes, Erika da Cruz
Erustes, Adolfo G.
Leão, Anderson H. F. F.
Abílio, Vanessa C.
Zuardi, Antonio W.
Hallak, Jaime Eduardo C.
Crippa, José Alexandre
Bincoletto, Claudia
Ureshino, Rodrigo P.
Smaili, Soraya S.
Pereira, Gustavo J. S.
-
Funding
Funding for this research was provided by:
Fundação de Amparo à Pesquisa do Estado de São Paulo (2018/06260-8)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2020/08840-1)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2016/20796-2)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/02821-8)
Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/10863-7)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (001)
- License Information
-
More Information
Article History
Received: 6 February 2024
Revised: 23 December 2024
Accepted: 18 January 2025
First Online: 4 February 2025
Declarations
:
: J.A.C. reported receiving grants from the National Institute of Translational Science and Technology in Medicine and personal fees from the National Council for Scientific and Technological Development (CNPq 1 A) during the conduct of the study, being a co-owner of a patent for fluorinated cannabidiol compounds (licensed to Phytecs) and having a patent pending for a cannabinoid-containing oral pharmaceutical composition outside the submitted work. J.A.C. is a consultant and/or has received speaker fees and/or sits on the advisory board and/or receives research funding from Janssen-Cilag, EaseLabs Pharm, DSM-Pharm, Torrent, GreenCare, PurMed Global, BioSynthesis Pharma Group (BSPG), and Prati-Donaduzzi. J.A.C. reported receiving grants from FAPESP.
